テキサスにおけるB細胞リンパ腫の臨床試験
テキサス内の拠点で、B細胞リンパ腫に関する26件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- Baylor Scott & White Research Institute, Texas Oncology, Dallas
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06343311Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
被験者募集中観察研究
0歳〜38歳 · 全性別 · 2026/10/01更新 · NCT06131801A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Md Anderson Cancer Center, Houston
- Texas Oncology Austin Midtown, Round Rock
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06742996A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
- University of Texas Southwestern Medical Center, Dallas
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07439653A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
- MD Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06213311A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Texas Southwestern, Dallas
- MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
- M D Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05615636A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Methodist Children's Hospital, San Antonio
被験者募集中第1相
0歳〜18歳 · 全性別 · 2026/09/16更新 · NCT06173518Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Austin
- Research Site, Houston
- Research Site, San Antonio
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06526793A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- The University of Texas Md Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06634589A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06564038A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
- Clinical Trial Site, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06393738Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Texas Oncology - West Texas, Midland
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/31更新 · NCT07516093Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Texas Oncology - Northeast, Tyler
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07520006Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Baylor University Medical Center, Dallas
- Texas Transplant Institute, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT05826535A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Lumi Research, Kingwood
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05254743Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- M D Anderson Cancer Center, Houston
被験者募集中第1/2相
12歳〜80歳 · 全性別 · 2026/08/07更新 · NCT05092451A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- St. David's South Austin Medical Center, Austin
- University of Texas Southwestern Medical Center, Fort Worth
- MD Anderson Cancer Center, Houston
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07188558A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
- The University of Texas M D Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/29更新 · NCT05773040DALY II USA/ MB-CART2019.1 for DLBCL
- UT Southwestern Medical Center, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- Texas Transplant Institute, San Antonio
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
- MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/07更新 · NCT06792734Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
- The University of Texas M. D. Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/01更新 · NCT07283679The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
被験者募集中第1/2相
12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- SCRI, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/11/14更新 · NCT05643742Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
- Sarah Cannon - St. David South Austin Medical Center, Austin
被験者募集中第1/2相
18歳〜80歳 · 全性別 · 2025/08/24更新 · NCT05607420Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- University of Texas, Southwestern, Dallas
- Cook Children's Hospital, Fort Worth
- Texas Children's Hospital/Baylor College of Medicine, Houston
被験者募集中第1相
1歳〜21歳 · 全性別 · 2024/12/06更新 · NCT05476770ClinicalTrials.govより、2026/10/03時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。